17 research outputs found

    Magnetic Removal of Micro‐ and Nanoplastics from Water—from 100 nm to 100 µm Debris Size

    Get PDF
    Clean water is one of the most important resources of the planet but human‐made contamination with diverse pollutants increases continuously. Microplastics (<5 mm diameter) which can have severe impacts on the environment, are present worldwide. Degradation processes lead to nanoplastics (<1 µm), which are potentially even more dangerous due to their increased bioavailability. State‐of‐the‐art wastewater treatment plants show a deficit in effectively eliminating micro‐ and nanoplastics (MNP) from water, particularly in the case of nanoplastics. In this work, the magnetic removal of three different MNP types across three orders of magnitude in size (100 nm–100 µm) is investigated systematically. Superparamagnetic iron oxide nanoparticles (SPIONs) tend to attract oppositely charged MNPs and form aggregates that can be easily collected by a magnet. It shows that especially the smallest fractions (100–300 nm) can be separated in ordinary high numbers (1013 mg−1 SPION) while the highest mass is removed for MNP between 2.5 and 5 µm. The universal trend for all three types of MNP can be fitted with a derived model, which can make predictions for optimizing SPIONs for specific size ranges in the future.Water contamination with pollutants like micro‐ and nanoplastics is continuously increasing with drastic consequences for flora and fauna. Surface modified superparamagnetic iron oxide nanoparticles (SPIONs) can trigger the formation of magnetically collectable agglomerates of diverse polymers of different sizes (100 nm–100 µm). A derived model may help to tailor the SPIONs in future toward a specific plastic size. image Deutsche Bundesstiftung Umwelt http://dx.doi.org/10.13039/100007636Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/50110000165

    Remediation of charged organic pollutants—binding motifs for highly efficient water cleaning with nanoparticles

    Get PDF
    AbstractMany charged organic molecules behave as persistent and hazardous pollutants with harmful effects on human health and ecosystems. They are widely distributed related to their charged molecular structure that provides water solubility. In order to track the fate and behavior of such pollutants, charged dyes with specific absorption in the visible spectra serve as convenient model compounds. We provide a platform of smart adsorbers that efficiently remediate positively and negatively charged dyes (crystal violet and Amaranth) from water. Metal oxide nanoparticles serve as a core with an intrinsically large surface area. The surface potential was tuned towards positive or negative by decorating the cores with self‐assembled monolayers of dedicated long‐chained phosphonic acid derivatives. Selective remediation of the dyes was obtained with corresponding oppositely charged core‐shell nanoparticles. Mixed dye solution can be cleaned by a cascade approach or by applying both particle systems simultaneously. The removal efficiency was determined as a function of particle concentration via UV‐spectroscopy. The results of remediation experiments at different pH values and using superparamagnetic iron oxide nanoparticle cores lead to a simple process with recycling capability.</jats:p

    TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes

    Get PDF
    Background: Despite advancements in the treatment of primary and metastatic breast cancer, many patients lack a durable response to these treatments. Patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2(HER2)-positive breast cancer who do not have a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a very poor prognosis. Tumor-infiltrating lymphocytes (TILs) have been identified as a predictive marker for pCR after NACT in TNBC and HER2-positive breast cancer. These patient populations could also be suitable for novel treatment strategies including neoepitope-based therapies. This work analyses the effect of TILs on the pCR in neoadjuvantly treated patients in the TILGen study and presents the procedures aimed at establishing neoepitope-based therapies in this study. Methods: Neoadjuvantly treated HER2-positive and TNBC patients were eligible for the presented analysis concerning the association between TILs and pCR. A total of 146 patients could be identified within the TILGen study. TILs were evaluated as percentage of stromal tumor tissue in core biopsies at primary diagnosis. The phenotype ‘lymphocyte-predominant breast cancer' (LPBC) was associated with pCR by logistic regression adjusted for estrogen receptor status, progesterone receptor status, HER2 status, age at diagnosis, and grading. Results: LPBC was seen in 24 (16.4%) patients. In this patient group, 66.7% achieved a pCR, while the pCR rate was 32.8% in patients with a low TIL count. The adjusted odds ratio was 6.60 (95% confidence interval 2.02-21.56; p < 0.01). Conclusion: TILs are a strong predictor of pCR in TNBC and HER2-positive breast cancer patients. Implications for the use of this information including the effect on prognosis might help to identify patients most likely to benefit from a neoepitope-based therapy approach

    Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

    Get PDF
    Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. Methods: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. Results: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. Conclusion: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues

    VIERTES KAPITEL. Die Weihnachtsfeier

    No full text

    PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer

    Get PDF
    PIWI-like 1 and PIWI-like 2 play a role in stem cell self-renewal, and enhanced expression has been reported for several tumor entities. However, few studies have investigated PIWI-like 1 and PIWI-like 2 expressions in breast cancer subtypes regarding prognosis. Therefore, we examined protein expression in a large consecutive cohort of breast cancer patients and correlated it to breast cancer subtypes and survival outcome. PIWI-like 1 and PIWI-like 2 expressions were evaluated using immunohistochemistry in a cohort of 894 breast cancer patients, of whom 363 were eligible for further analysis. Percentage and intensity of stained tumor cells were analyzed and an immunoreactive score (IRS) was calculated. The interaction of PIWI-like 1 and PIWI-like 2 showed a prognostic effect on survival. For the combination of high PIWI-like 1 and low PIWI-like 2 expressions, adjusted hazard ratios (HRs) were significantly higher with regard to overall survival (OS) (HR 2.92; 95% confidence interval (CI) 1.24, 6.90), disease-free survival (DFS) (HR 3.27; 95% CI 1.48, 7.20), and distant disease-free survival (DDFS) (HR 7.64; 95% CI 2.35, 24.82). Both proteins were significantly associated with molecular-like and PAM50 subgroups. Combining high PIWI-like 1 and low PIWI-like 2 expressions predicted poorer prognosis and both markers were associated with aggressive molecular subtypes

    Indications and Route of Hysterectomy for Benign Diseases. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry No. 015/070, April 2015)

    Get PDF
    Background: Official guideline "indications and methods of hysterectomy" to assign indications for the different methods published and coordinated by the German Society of Gynecology and Obstetrics (DGGG), the Austrian Society of Gynecology and Obstetrics (OEGGG) and the Swiss Society of Gynecology and Obstetrics (SGGG). Besides vaginal and abdominal hysterectomy, three additional techniques have been implemented due to the introduction of laparoscopy. Organ-sparing alternatives were also integrated. Methods: The guideline group consisted of 26 experts from Germany, Austria and Switzerland. Recommendations were developed using a structured consensus process and independent moderation. A systematic literature search and quality appraisal of benefits and harms of the therapeutic alternatives for symptomatic fibroids, dysfunctional bleeding and adenomyosis was done through MEDLINE up to 6/2014 focusing on systematic reviews and meta-analysis. Results: All types of hysterectomy led in studies to high rates of patient satisfaction. If possible, vaginal instead of abdominal hysterectomy should preferably be done. If a vaginal hysterectomy is not feasible, the possibility of a laparoscopic hysterectomy should be considered. An abdominal hysterectomy should only be done with a special indication. Organ-sparing interventions also led to high patient satisfaction rates, but contain the risk of symptom recurrence. Conclusion: As an aim, patients should be enabled to choose that therapeutic intervention for their benign disease of the uterus that convenes best to them and their personal life situation
    corecore